Background and Objectives: the cardiovascular adverse events including mortality and heart
failure, persist significantly during the first months after the acute phase of ST-segment …

Background Midregional proadrenomedullin (MR‐pro ADM) has demonstrated prognostic
potential after myocardial infarction (MI). Yet, the prognostic value of MR‐pro ADM at …

Objectives: This study sought to assess the prognostic impact of midregional pro-
adrenomedullin (MR-proADM) after an acute myocardial infarction (AMI). Background …

Background Biomarkers may contribute to risk stratification in coronary heart disease (CHD).
We examined whether plasma midregional proadrenomedullin (MR-proADM) concentration …

Background: Midregional pro-adrenomedullin (MR-proADM) and endothelin-1 have been
shown to predict mortality of patients with acute myocardial infarction. However, the …

Objective To assess the cardiovascular prognostic value of mid-regional pro-
adrenomedullin (MR-proADM) and compare this with B-type natriuretic peptide (BNP) and N …

Context: Cardiogenic shock (CS) still remains one of the main causes of death in acute
myocardial infarction (AMI). Objective: The aim of this study was to evaluate the prognostic …

Abstract BACKGROUND Midregional proadrenomedullin (MR-proADM) is a newly identified
prognostic marker in heart failure. We evaluated the prognostic impact of MR-proADM in a …

Background Diabetes mellitus (DM) is associated with an adverse outcome in heart failure
(HF). Increased concentrations of midregional proadrenomedullin (MR-proADM) have been …

Abstract Background: Midregional proadrenomedullin (MR-proADM) is emerging as a
prognostic biomarker for detecting the failure of multiple organs. Establishment of …